• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Population references values

Reference values of the MRS in the “normal population”

Understanding the MRS score requires some background understanding of the prevalence of climacteric complaints or problems in the background population. Initial standardized values and definitions for the MRS were published as a single table 2. These values were based on the German population.

Are these reference values applicable to other countries/cultures?

Mean values (SD) of the MRS total score and the three domains are depicted in the attached table.

The mean values of the total score and the 3 domain scores do not show a statistically significant difference between populations.  Therefore, there is no evidence to exclude direct comparisons of MRS values between Europe and the USA.

However, the total psychological and somatic scores were systematically higher in Latin America and systematically (significantly) lower in Asia (Indonesia) than in Europe/North America. The urogenital scores were significantly lower in Latin America/Indonesia than in Europe/US.  It is unclear whether the symptoms and pathophysiology differ across groups or if the subject perception of some symptoms varies due to cultural factors.  However, a direct comparison of MRS scores between Europe/North America on the one side and regions in Latin America and Asia should be considered cautiously.

How are mean values affected by country and culture?

Mean values also show a different distribution across the four categories of complaint severity (no symptoms, mild, moderate, and severe symptoms) depending on where the scale is used. The attached table shows the prevalence of symptoms populating the four severity scores by region. The comparison of the prevalence (and 95% confidence interval) showed that the above-discussed differences between Europe/US and Latin America or Indonesia very much depend on the severity of complaints.

When the data is analyzed by sub-domain, differences seen in the psychological domain appear less impressive. The urogenital and somatic domains show the largest differences across regions. It is unclear whether this is due to different perceptions of identical symptoms, differences in the appearance of symptoms, or both. However, it needs to be considered when direct comparisons among different cultures are intended.

The prevalence of different “degrees of severity” of menopausal symptoms measured with the MRS was found to be almost identical in the aggregate of Europe and North America.

Intra-individual comparisons

Differences between regions, however, do not affect intra-individual comparison (e.g., pre-/post- therapy), and it may also have minimal effect on the comparison of time-related changes between countries. Although definitive research on this topic is missing.


2. Potthoff P, Heinemann LAJ, Schneider HPG, Rosemeier HP, Hauser GA. Menopause-Rating Skala (MRS): Methodische Standardisierung in der deutschen Bevölkerung. Zentralbl Gynakol 2000; 122:280-286.

sidebar

Expertise

  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
    • Aging Male Symptoms Scale
    • Menopause Rating Scale
    • Scale for Quality of Sexual Function
    • Short Term Hormone Effect Scale
    • Research team
  • Data collection instruments

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.